Protocol Tip of the Week
If you're on a chronic or high-dose rapamycin protocol (not the pulsed 5-10mg/week most longevity docs use), get your IgG checked. This week's data reinforces that mTOR inhibition suppresses humoral immunity in a dose-dependent way — don't wait for a sinus infection that won't quit to find out you're hypogammaglobulinemic.Study 1: Senescent Cells Have a Weak Spot — And It's Not Dasatinib/Quercetin
A new mechanistic paper in Science Advances (PMID: 42912996) found that cells entering therapy-induced senescence become dependent on Inhibitor of Apoptosis Proteins (IAPs) to survive — essentially, the death receptor pathway (TRAIL/Fas) gets activated during senescence entry, and the only thing keeping these cells alive is IAP overexpression blocking the apoptosis signal they've already triggered. Knock out the IAPs, and the senescent cells die.This matters because the senolytic field has been stuck on the same two toolkits for a decade: dasatinib+quercetin and fisetin, both of which are blunt instruments with mediocre selectivity. IAP antagonists (Smac mimetics) are already in oncology trials, which means there's a faster path to human data than starting from scratch — but don't get ahead of yourself. This is in vitro/cancer-model work studying "therapy-induced senescence" (i.e., senescence from chemo/radiation), not the garden-variety senescent cell burden you're accumulating from just getting older. Translating this to a geroprotective senolytic protocol is a few mechanistic leaps away, and IAP antagonists come with their own toxicity baggage (they're cancer drugs for a reason). File this under "interesting new drug class to watch," not "add to stack."
Study 2: Your Kidneys Might Be Aging Your Heart
A review in Kidney360 (PMID: 42911667) lays out the case that cellular senescence is the mechanistic bridge connecting chronic kidney disease (CKD) to cardiac fibrosis — the senescent cell burden that builds up in failing kidneys doesn't stay local, it drives a systemic SASP (senescence-associated secretory phenotype) that fibroses the heart. This creates a feed-forward loop: kidney senescence → cardiac fibrosis → reduced cardiac output → reduced renal perfusion → more kidney senescence.The practical takeaway here isn't a new drug — it's a biomarker argument. Most longevity-minded people track lipids, HbA1c, maybe hs-CRP, and ignore kidney function until eGFR tanks. This paper (and the broader senescence-CKD literature it synthesizes) makes a decent case that eGFR, cystatin C, and albuminuria deserve a permanent spot on your annual panel as early-warning proxies for systemic senescent burden, not just "kidney health." That said — this is a review, not new data. It's organizing existing mechanistic literature into a tidy narrative, which is useful for building your mental model but shouldn't be mistaken for a breakthrough. The real test will be whether senolytic trials targeting CKD populations (there are a few small ones ongoing) show cardiac fibrosis improvement as a secondary endpoint.